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ABSTRACT 
Asthma is a disorder characterized by symptoms such as wheezing, shortness of breath, chest tightness or 
coughing. It is a chronic inflammation in the airways and the inflammation is usually accompanied by 
limitations in airflow as a result of hyper-secretion of mucus and broncho-constriction. Asthma 
commonly coincides with other allergic diseases such as allergic sensitization and rhinoconjunctivitis. 
The prevalence of asthma and allergy in children is highest in affluent countries with up to 20% in 
English speaking countries. Asthma and allergic disease are complex disorders and have long been 
known to be influenced by both heritable components and environmental factors.  
The overall aim with this thesis was to investigate asthma susceptibility genes and their 
genetic role, biological dependency, as well as how they interact in a context-dependent manner, either 
with other genes (I) or with environmental factors (II). We studied the functional difference between 
splice variants of a previously identified asthma susceptibility gene showing unique expression patterns 
in asthmatic patients (III). We also aimed to define global gene expression patterns in asthmatic children 
that could reveal novel insight about characteristics of severe therapy-resistant asthma in children (IV). 
In study I, we examined the biologically linked asthma susceptibility gene Tenascin C 
(TNC) and its genetic role in asthma and allergy. We also investigated the biological and genetic 
interactions between TNC and the previously genetically identified asthma susceptibility gene 
Neuropeptide S receptor 1 (NPSR1). In study II, we investigated the interactive effects of NPSR1 and 
environmental exposures related to farming lifestyle, as well as the effect of lipopolysaccharide (LPS), a 
proxy for farm animal exposure, on NPSR1 expression. We provide data showing that TNC has an 
independent genetic role in certain allergic diseases. We show biological interplay by a dose-dependent 
upregulation of TNC expression upon NPS-NPSR1 activation, and we conclude that interaction occurs 
between TNC and NPSR1altering the outcome of asthma and allergy. Genetic variations in NPSR1 are not 
only dependent on other genes, but can also modify the effect of the environment, on the development of 
allergic diseases. Farm animal contact and farm milk consumption, introduced early in a child’s life, has 
been proven to show protective effects against development of allergic diseases. In study II, we 
demonstrate that the protective effect of farm animal contact can be further modified depending on 
genetic variations in NPSR1, especially if the contact is initiated later in life. We also identified increased 
NPSR1 expression upon LPS stimulation of human monocytes. From these two studies we can confirm 
that interactive effects, both biological and genetic, are important in the development of asthma and 
allergy. We could also see that the genetic dependency is most likely to occur when the main effect of the 
individual genes, or environmental factors, investigated are not that dominant.  
In study III, we investigated the function of NPSR1 in more detail. The NPSR1 gene 
encodes two functional receptor variants (A and B) with distinct intracellular C-termini. Previous studies 
have illustrated different expression pattern, especially in asthmatic airways, between the two receptor 
variants. We could in study III demonstrate that, upon activation, both receptor variants A and B signals 
through the same pathways and induces expression of in principal identical set of genes. However, with 
few exceptions, variant A constantly induced stronger signaling effects than variant B. The effect was 
seen on both second messenger level and on down-stream gene expression. These findings suggest an 
isoform specific link to NPSR1s role in allergic airways. 
Among children with asthma around 5% suffer from chronic symptoms and/or severe 
exacerbation despite extensive treatment. The causes of this severe, therapy resistant asthma in childhood 
are poorly understood. In study IV we aimed to investigate global differences in gene expression in white 
blood cells from patients with severe, therapy-resistant asthma (SA, n=20), patients with controlled but 
persistent asthma (CA, n=20) and a group of healthy controls (Ctrl, n=19). We identified 1378 genes to 
be significantly differentially expressed between any of the contrasts (CA-Ctrl, SA-CA, SA-Ctrl) 
demonstrating that there are differences in gene expression between groups of asthma. Functional 
annotation and enrichment analysis identified three significantly differentially expressed pathways; bitter 
taste transduction, (upregulated mostly in SA), natural killer cell mediated cytotoxicity (upregulated in 
CA) and N-glycan biosynthesis (downregulated in SA).  The bitter taste receptor family (TAS2Rs) has 
recently been shown to play a protective role in asthmatic airways e.g. by dilation of airways upon 
stimulation with bitter substances. Our finding is the first to propose a role for TAS2Rs in asthma outside 
the airway system. In conclusion our data indicates a separation in gene expression patterns between 
children with severe, therapy resistent asthma and controlled asthma, and suggests pathways revealing 
novel insight about the characteristics of severe therapy-resistant asthma. 
From the finding in this thesis we can conclude and confirm that there is always a 
complex interplay between several genes and environmental factors altering the outcome of allergic 
disease. It is important to investigate these genes in more detail to unravel the functional mode of action. 
We can also see that by investigating clear defined subgroups of asthma it might be possible to identify 
new therapeutic targets for asthma. 
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1 POPULÄRVETENSKAPLIG SAMMANFATTNING 
I varje cell i vår kropp finns förpackningar, kromosomer som består av DNA, som i sin 
tur består gener. Av varje gen finns det två kopior, av vilka hälften kommer från 
mamman och hälften från pappan och vi har en uppsättning om ca 20,500 olika gener i 
varje cell. I generna, och runtomkring dem, finns förändringar som gör oss unika, dels 
ärvda från många generationer tillbaka, men även nya.  
 
Många av våra vanligaste sjukdomar, såsom bipolära psykoser, hjärt- och kärl problem, 
reumatism, diabetes och astma styrs både av miljöfaktorer och ärftliga komponenter 
(såsom gener). Dessa folksjukdomar är så kallade komplexa sjukdomar. I komplexa 
sjukdomar är det ett samspel mellan arv och miljö som utgör själva risken för att 
utveckla sjukdom eller inte. Astma är en kronisk luftvägs sjukdom som kännetecknas 
framförallt av svårigheter att andas. Astma förekommer ofta tillsammans med andra 
allergiska symptom, så som hösnuva och allergi. 
 
De faktorer som tros påverka utfallet av astma och allergi är främst; (a) Miljöfaktorer - 
där den mångfaldiga bakteriefloran man utsätts för på ett jordbruk (kontakt med djur, 
opastöriserad mjölk, etc.) anses ha en skyddande effekt och rökning, tidiga luftvägs 
infektioner etc. medför en större risk. (b) Ärftliga faktorer - runt 100 gener har 
identifierats med möjlighet att öka risk för sjukdomen. Många ärftliga faktorer är 
kopplade till funktioner i immunförsvaret eller luftvägarna, men flera gener har i 
dagsläget en okänd koppling till astma. Vad vetenskapen kommit fram till de senaste 
åren är att det sannolikt är förändringar i ett flertal gener som i samspel med flera olika 
miljöfaktorer, orsakar astma och allergi. 
 
I denna avhandling har vi utforskat hur förändringar i gener kan påverka risken att 
utveckla astma och allergi. Hur dessa förändringar i olika gener samarbetar med 
varandra och med miljön för att antingen öka eller minska risken för sjukdom, och hur 
förändringarna påverkar genes funktion. Vi har även undersökt om det finns skillnader i 
genernas uttrycksnivåer mellan astmapatienter som är svårt sjuka, där inte ens 
behandling hjälper, och de som är sjuka men svarar på sin medicinering.  
 
I studie I har vi undersökt förändringar i gener som är kopplade till astma. Vi har 
studerat hur dessa förändringar på DNA nivå (exempelvis SNPs) i sig själva kan 
påverka risken att utveckla astma och andra allergiska sjukdomar. Även hur generna 
kan samarbeta med varandra, gener emellan, och med olika miljö faktorer för att 
antingen ge en skyddande effekt eller en ökad risk för sjukdom. Med våra 
forskningsresultat kan vi bekräfta att detta samarbete pågår i kroppen. Vi visar på nya 
kombinationer av gener (Tenascin C, TNC och Neuropeptide S receptor 1, NPSR1) vars 
förändringar både kan öka och minska risken för astma och allergiska sjukdomar.  
 
Tidigare studier har påvisat att barn som bor på en bondgård, har regelbunden kontakt 
med djuren på gården, och dricker opastöriserad mjölk utvecklar ett skydd mot astma 
och allergi. Detta gäller speciellt om denna kontakt inleds redan under fosterstadiet, 
dvs. den blivande mamman vistas i dessa miljöer, eller under de första åren. Vi kan i 
studie II visa att, i kombination med vissa förändringar i genen NPSR1, har dessa 
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miljöfaktorer även en skyddande effekt när de kommer in senare under ett barns 
uppväxt. 
 
I studie III studerade vi funktionen av genen NPSR1 i mer detalj. NPSR1 är en 
mottagare, en s.k. receptor, som sitter på cellens yta, och tar emot signaler från 
omgivningen och genom receptorn förmedlas dessa signaler in i cellen. Detta startar en 
kedja av händelser som talar om vad cellen ska göra. Det finns två varianter av NSPR1, 
A och B, och det som skiljer dem åt är den biten av receptorn som befinner sig inne i 
cellen. A varianten är den vanligaste förekommande i kroppen av de två men i studier 
på patienter med astma har man sett att B varianten är vanligare på vissa celler i 
luftvägarna. I cellkulturer på laboratoriet har vi studerat om ”svaret” (aktivering av 
andra proteiner och gener inne i cellen), som cellerna ger när de olika 
receptorvarianterna signalerar in till cellen, skiljer sig åt. Vad vi har kunnat påvisa är att 
variant A ger ett starkare svar än B varianten.  
 
Inom astma finns det olika svårighetsgrader av symptom. Vissa patienter uppvisar 
mildare symptom, andra svårare symptom, och ytterligare några är svårt sjuka och 
svarar inte på behandling. För den sistnämnda gruppen är det viktigt att undersöka vad 
det är som gör att de inte svarar på behandling. Det långsiktiga målet är att identifiera 
faktorer som skulle kunna leda till nya läkemedel för denna patientgrupp. I studie IV 
har vi analyserat skillnader i genernas uttryck i vita blodkroppar från de astmatiker som 
är svårt sjuka och inte svarar på behandling, och de som har något mildare symptom 
och svarar bra på behandling. Vad vi kunde påvisa var att det fanns skillnader i 
genernas uttryck mellan grupperna. Patienter med mildare symptom hade i regel ett 
högre uttryck av de gener som är kopplade till immunförsvaret. Den svårt sjuka 
gruppen visade i stället ett högre uttryck av en grupp gener som hör till gruppen av 
smakreceptorer som i munnen känner av bittra substanser. Denna grupp av receptorer 
har nyligen identifierats även i luftvägarna och tros ha en skyddande effekt mot astma. 
Vad dessa receptorer har för funktion i vita blodkroppar återstår att se, men dessa fynd 
kan ge oss ledtrådar om vad som orsakar terapiresistens hos svårt sjuka astmatiker. 
 
Sammanfattningsvis kan vi i denna avhandling påvisa ytterligare bevis för att 
förändringar i gener samarbetar med varandra och med olika miljöfaktorer och därmed 
påverkas utfallet av astma och allergiska sjukdomar. Vi visar på funktionella skillnader 
mellan två varianter av en receptor som tidigare kopplats till astma. Genom att jämföra 
olika patientgrupper med astma, de som svarar på behandling mot de som inte svarar på 
behandling, kan vi identifiera nya nätverk av gener som skiljer dessa grupper åt. På sikt 
skulle dessa resultat möjligen kunna leda fram till nya läkemedel mot astma. 
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2 BACKGROUND 
 
2.1 INHERITANCE 
Many diseases, as well as characteristics of our body rely mainly or partially on our 
inheritance. Each individual has the same set of genes but there are some distinct 
changes in the genome that make us unique. These changes can be passed on from 
generation to generation, and are thus inherited. In some cases, variations in one gene 
are both necessary and sufficient for a character to be expressed. Such characteristics 
are called Mendelian, or monogenic. Cystic fibrosis is an example of a monogenic 
disease caused by alterations in the gene CFTR.1 However, most of our traits are non-
Mendelian and determined by a combination of alterations in several genes and also 
influenced by environmental factors. Such characters are called multifactorial or 
complex traits/disorders. Asthma is a typical complex disease where the features of the 
disease are influenced both by the genetic make-up composed of alterations in several 
genes, as well as by exposure to various environmental factors. Other common 
complex disorders are bipolar mental disorders, coronary artery disease, Crohn´s 
disease and diabetes. In this thesis I will discuss disease, inheritance, identification and 
consequences of inheritance in the context of complex disorders.   
 
 
2.2 ASTHMA AND ALLERGIC DISEASE IN CHILDREN 
 
2.2.1 Definition and prevalence 
Allergic disease is a broadly defined term that includes several phenotypic 
characteristic such as allergic sensitization, asthma, wheeze, and rhinoconjunctivitis 
(hay fever). Some of these features commonly coincide. Allergic sensitization is a 
response in the immune system against, in normal cases, harmless substances such as 
certain food or other allergens, and usually defined by an increase in specific IgE 
antibodies (in plasma), or a positive skin prick test. Asthma is characterised by chronic 
inflammation in the airways. The inflammation is usually accompanied by limitations 
in airflow as a result of hyper-secretion of mucus and broncho-constriction causing 
symptoms like wheezing (a whistling sound during breathing), shortness of breath, 
chest tightness or coughing. Asthma occurs in different degrees of severity and as 
allergic (combined with allergic sensitization) or non-allergic asthma. Currently, 
asthma can roughly be classified clinically as mild, moderate, or severe based on the 
presentation of symptoms in relation to the level of medication.2, 3Asthma in children is 
closely related to wheeze and the severity of asthma is often defined by the number of 
reoccurring wheezing episodes.4 Rhinoconjunctivitis is characterised by sneezing, nasal 
congestion and itching of the nose, eyes or throat and is in children usually associated 
with an allergic sensitization to pollen or pets. The cause of asthma and allergic 
disorders is currently unknown. However, it is very likely that genetic and 
environmental factors interact with each other to determine the outcome of asthma.5  
 
The prevalence of asthma and allergic disease has increased in developed countries 
over the last century and asthma is now one of the most common chronic diseases of 
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childhood. The International Study of Asthma and Allergies in Childhood (ISAAC) 
demonstrates that the prevalence of asthma symptoms varies worldwide, with English 
speaking countries and Latin America having the highest prevalence, up to 20%. In 
Africa, the Indian Sub-continent and in the Eastern Mediterranean, the disease appears 
to be less often recognized but more severe. The trend seen is an increased prevalence 
in more affluent countries but a more severe phenotype in less affluent countries.4 
Among children with asthma, around 5% suffer from severe asthma, characterized by 
chronic symptoms and/or severe exacerbations despite drug treatment.6 The prevalence 
of rhinoconjunctivitis in the same study was on an average 15% for current symptoms.7 
 
The clinical diagnosis of asthma is usually based on patterns of symptoms, response to 
therapy, together with clinical testing of e.g. lung capacity.8 Lately it has been 
discussed if clinically defined asthma is one disease or composed of several sub-
diseases. Proposed classifications based on combined data on clinical features, 
physiology, immunology, pathology, genetics, environment, response to treatment and 
other factors might in the future lead to new, more specific definitions.9, 10 Currently, all 
available treatments, e.g avoidance of allergens and irritants together with medications 
such as inhaled corticosteroids and bronchodilators, are non-curative and only provide 
symptom prevention or relief. 
 
 
2.2.2 Factors influencing the development of asthma and allergic 
disease 
Asthma is a complex disorder and thought to be influenced by several different factors.8 
These can either act as risk factors, or protect against developing the disease. Examples 
of such factors are: a) The local environment- living on a farm and consumption of 
farm-produced products is believed to have a protective effect11, whereas smoking, 
pollution, and exposure to molds is negative for the outcome12; b) Genetics- early twin 
studies13, 14 to modern genome wide associations studies (GWAs)15 all point towards a 
high heritable factor in asthma; c) Infections- since the early 1970s and up to now, 
studies have shown a relationship between viral lower respiratory tract infections and 
asthma later in childhood12, 16; d) Gender, age, family size, obesity, ethnicity, and 
antibiotics during early infancy are also factors thought to influence the development of 
asthma.12, 17, 18 
 
There has been an accelerated increase in the prevalence of asthma and allergies in the 
Western societies over the past decades. To explain this phenomenon the term “hygiene 
hypothesis” was coined in 1989.19 The hygiene hypothesis states that due to the 
“Westernized” lifestyle, e.g. smaller family size, improved living standards and better 
personal hygiene, children are exposed to a “cleaner” environment, with fewer 
infections resulting in an increased risk of developing allergic diseases. Recent data still 
show an increase of asthma and allergy in the affluent world. 4 However, this may not 
be the consequence of a “cleaner” environment in the previous sense, but rather due to 
a deficiency in exposure to a diverse microbial environment in.20-22 The main proposed 
cellular mechanism behind asthma and allergy is thought to be a skewed balance in the 
immune response between the two white blood cell groups T helper cells 1 and 2 (TH1-
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TH2). Shifts in balance towards TH1would lead to autoimmune disease whereas a shift 
towards TH2 would lead to allergic disorders. A positive exposure to a diversity of non-
pathogenic microorganisms, together with other factors, is now suggested to regulate 
the immune system and to maintain the balance between TH1 and TH2 cells.23 Since the 
protective effects are no longer believed to be due to an “unhygienic” environment, but 
rather due to a diverse exposure to a beneficial bacterial flora the term “hygiene 
hypothesis” has been proposed to be replaced by the “microbial deprivation 
hypothesis”.20 
 
 
2.3 THE HUMAN GENOME 
 
2.3.1 Composition of the genome 
The human genome is made up of strings of deoxyribonucleic acid (DNA) molecules 
consisting of unique nucleotide bases, i.e. adenine (A), cytosine (C), guanine (G) and 
thymine (T). Continuous variation of the composition of these four bases is what makes 
up all our genes. DNA normally occurs as a double helix, comprising two 
complementary strands where a distinct stretch of DNA, used as a template to 
synthesize a functional complementary ribonucleic acid (RNA) molecule (which in 
most cases encodes for a protein), is called a gene. According to the latest estimate 
there are around 20,500 protein coding genes in the human genome. 24 The double helix 
DNA structure is rolled up on histones and twisted and twisted until it is packed into a 
chromosome. There are 23 chromosome set in the human body and most cells (except 
the sperm and egg cells, which only have one) carry two copies of each chromosome 
(44 and XX for females and 44 and XY for males). Each unique gene is used as a 
template to synthesize (RNA). RNA molecules can be divided into two broad classes, 
messenger RNA (mRNA); that serves as templates for protein production, and 
noncoding RNAs (ncRNA); which are RNA molecules that do not translate into 
proteins. Included in the group of ncRNA are among others, ribosomal RNA (rRNA), 
transfer RNA (tRNA), small nuclear RNA (snRNA), microRNA (miRNA). The 
ncRNA have important functions in building blocks in ribosomes, perform functions as 
carriers of amino acids during translation and regulating the expression of other 
genes.25 Genes, usually, consists of both exons and introns which make up the template 
for RNA. The introns are however removed by splicing and it is only the exons that 
constitute the final mRNA (or ncRNA), which in turn can be translated into a protein 
(Fig. 1). The proteins constitute the cornerstones in building the body and provide the 
functional machinery that is utilized by all cells to perform their tasks.  
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Figure 1. DNA is made up by combinations of nucleotides with either an A, C, G or T base attached to it. 
A stretch of DNA makes up a gene which in turn is split up in exons and introns. The exons serve as the 
template for mRNA which codes for the proteins. 
 
 
2.3.2 Sequence variations in the genome 
A unique chromosomal location defining the position of a gene or a DNA sequence is 
termed a locus (or several loci). An alternative version of a gene is called an allele. For 
one gene there are two alternative alleles in each cell, one on each chromosome, i.e. one 
inherited from the father and the other from the mother. An allele does not have to be 
the entire gene but can be designated to one specific nucleotide. The human genome 
contains numerous variations which can occur both within and among human 
populations. These variations are named single nucleotide polymorphisms (SNPs). 
Currently there are 12 million SNPs deposited in the GenBank® database 
(http://www.ncbi.nlm.nih.gov/genbank). A SNP can occur within an exon (coding 
SNP) or elsewhere in the genome (non-coding SNP).  
 
A person is homozygous (HoZ) if it has the same base in a specific position (e.g. a “C” 
or a “T” on both alleles). A person is said to be heterozygous (HeZ) if the base in a 
specific position differ between the alleles (e.g. a “C” in one allele and a “T” on the 
other) (Fig. 2). Alternatively, the individual is said to have a “CC”, a “CT” or a “TT” 
genotype. If “C” is the common allele then “T” will consequently be the least frequent, 
rare allele (Fig. 2). The frequency of this rare or minor allele in the population is 
termed minor allele frequency (MAF). There are other variations in the human genome 
as well; copy number/neutral variations (CNVs), which is when a gene/part of a gene is 
deleted, duplicated, inverted or translocated, and epigenetic changes, which can be 
defined as “the structural variation of chromosomal regions so as to register, signal or 
enable altered activity states”.26 The epigenetic changes do not affect the underlying 
DNA code but rather modifies how it is expressed. 
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Figure 2. Illustrating three possible combinations of the two alleles. A person can either be homozygous 
(HoZ) or heterozygous (HeZ) for a genetic variation. The least frequent genotype (i.e.  TT) will be the 
combination of the rare alleles (i.e. T). 
 
When a particular genotype present at one locus is independent of a genotype at a 
second locus, the genotypes are said to be in linkage equilibrium. When, on the other 
hand, a particular genotype present at one locus is dependent of a genotype at a second 
locus, the genotypes are said to be in linkage disequilibrium (LD). LD is a non-random 
association of genotypes. The genotypes within such a region form blocks called LD 
blocks. LD blocks are separated by hotspots of recombination and the genotypes in an 
LD block are most likely inherited together. 
 
Although many of the variations discussed above do not lead to any visible phenotypic 
distinction between people, taken together all these variations result in a human-to-
human genetic variation of approximately 0.5%.27 As a result, each person carries an 
exclusive genome with a unique risk for each developing diseases, respond to the 
environment and respond to drug treatment. Of note, we are still 99.5% alike each 
other.  
 
 
2.3.3 Finding disease genes: from past to presence 
In 1953 the DNA double helix was discovered by Watson and Crick and the findings 
made way for new research in the field of genetics.28 Since then, the field has simply 
exploded. In1990, the international Human Genome Project (HGP) was launched, with 
the goal to sequence the entire human genome. The project was completed and 
published in 200429, even though drafts of the human genome sequence, now 
performed as a race between the publically founded HGP and the private company 
Celera Genomics, were published already 2001, presenting roughly 90% of the total 
sequence.30, 31 The drafts suggested that the genome contained 30,000-40,000 genes, 
not 100,000 as previously estimated.32 However this number has been revised after 
completion of the project and is now estimated to ~20,500 distinct protein-coding 
genes.24  
 
 
2.3.3.1 Linkage analysis 
During the past years, linkage studies and candidate gene association studies have been 
the main approach to identify susceptibility genes for complex genetic disorders. 
Linkage studies are performed on families with affected individuals. Each family 
member is genotyped for genetic markers that are evenly spread throughout, a 
candidate gene region or the whole genome covering all chromosomes. If a region is 
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identified that contains a higher than expected number of shared alleles among the 
affected individuals, the region is said to be linked to the disease in question. The main 
advantage of this approach, when used at the whole genome level, is that it is 
hypothesis-free. The disadvantage is that the regions identified are quite large and 
requires further fine-mapping, i.e. positional cloning. Even when fine-mapping is 
performed, the identified region might harbor several susceptibility genes with small 
effects that together create the linkage peak thus making it difficult to elucidate which 
are the true candidate genes. 
 
 
2.3.3.2 Candidate gene association studies 
Candidate gene association studies (used in study I) mainly focus on previously 
identified candidate genes. They are usually performed on groups of unrelated “cases” 
and an appropriate unrelated control group (“controls”). A certain number of tagging 
SNPs (see 2.3.3.3) or biologically interesting SNPs are genotyped in the gene in 
question and the frequency of each genetic variant is compared between cases and 
controls. A significantly altered frequency in cases vs. controls indicates that the 
genetic variant is related to disease susceptibility. The main advantage of association 
studies is that they are more easily powered, it is easier to obtain large numbers of 
unrelated individuals compared to collect large number of families. SNPs are used for 
case-control association studies both in small scale (candidate gene approach) and large 
scale (GWAs, see 2.3.3.4). Tests can be performed for either single SNP associations, 
which means that one SNP at the time is tested, or for a combination of SNPs in tight 
LD, a haplotype. Before any association analyses are performed, each SNP is tested for 
Hardy-Weinberg equilibrium (HWE), i.e. the allele frequencies received when 
genotyping the study groups are compared to the expected allele frequencies in a 
corresponding population. A deviation from HWE in random samples may indicate 
genotyping errors, leading to false conclusions.33   
 
 
2.3.3.3 The HapMap project 
In 2002, the international HapMap project was initiated to construct a genome-wide 
SNP database of common variations and to generate maps of stretches, or blocks, of 
DNA inherited together, i.e. SNPs in tight LD (http://www.hapmap.org).34 This was 
initially done for 269 subjects in 4 different populations. Use of information from the 
HapMap project facilitates association studies, since it enables genotyping of only those 
SNPs that tag the blocks, i.e. tagging SNPs, and not every SNP in the human genome. 
If a tagging SNP is associated to disease, it is likely that the causative SNP/SNPs are in 
that haploblock (for an example of a haploblock/LD plot, structure, see Fig. 5). During 
the progress of the HapMap project, the development of genotyping arrays also took 
place (i.e. SNP chips). These arrays contain spots for today up to ~ 2 million SNPs and 
allow for a quick and cost effective way of extensively genotype many individuals (one 
per chip) at the same time without prior hypotheses. 
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2.3.3.4 Genome wide association studies (GWAs) 
Based on the knowledge of tagging SNPs from HapMap, other genetic variants, and the 
development of SNP chips, large scale genome wide association (GWA) studies started 
to take place in 2005-6. Up to millions of SNPs can be tested for disease association in 
hundreds or thousands of individuals, which provides a great advantage over linkage 
analysis and candidate gene associations. The principle is the same as for regular case-
control association analyses with one important exception. When association studies 
are performed with few SNPs in a defined candidate gene or region, a statistic 
significance of p ≤ 0.05 is generally accepted. However, when many hundred thousands 
of SNPs are tested, as in GWAs, the number of tests performed will result in a large 
number of false positives if a p ≤ 0.05 would be used. This multiple testing needs to be 
corrected for and in GWAs, an association is only regarded as significant if p ≤ 5 x10-8 
(http://www.genome.gov/gwastudies). (See section 4.5.1 for more details on multiple 
testing) 
 
 
2.3.3.5 Next generation sequencing and the 1000 genomes project 
In parallel with the publication of an increasing amount of GWA studies, the 
sequencing technology has changed and vastly improved.  What previously took years 
to finish is now completed within weeks with the Next Generations Sequencing (NGS) 
technology.35 The major advantage over the array technology is that instead of only 
analyzing assigned spots, the whole genome can be investigated. The 1000 genomes 
project is a deep re-sequencing project, and an extension from the HapMap project 
aiming to provide detailed information on genetic variation using more than 1,000 
genomes from populations all around the world (http://www.1000genomes.org). The 
goal is to identify 95% of all variantions with a greater frequency than 1%. This will 
hopefully provide information to evaluate the common disease/ many rare variants 
hypothesis (see section 2.3.3.6). 
 
 
2.3.3.6 Common disease-common variants and the missing heritability 
Much hope was put in the genetic information that would be gained from GWA 
studies. However, taking into account all these efforts to connect genetic variation to 
complex disorders, the risk effects (estimated as odds ratios, ORs) of individual genes 
have still turned out to be notably lower than the estimated total genetic risk. The gap 
between the expected proportion of genetic factors in disease and the actual findings 
from GWAs has been termed the “missing heritability”.36 The search for susceptibility 
genes in GWAs was founded on the “common disease-common variant” hypothesis; 
i.e. the genetic influences on susceptibility to common diseases are attributable to a 
limited number of common variants present in more than ~5% of the population.32, 37 A 
possible explanation for the “missing heritability” has been that this hypothesis is not 
entirely correct, i.e. it is not only the common variants that contribute to common 
disease, but also the rare variants (less than ~0.5% frequent in the population). A new 
hypothesis was hence proposed; the “common disease-many rare variants” 
hypothesis.38 It states that there are many large effect rare variants in the population, 
and each case of a common genetic disorder is due to the summation of the effects of a 
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few of these rare variants. Other possible explanation to the missing heritability has 
been attributed to the structural variants such as copy number variation, inversions, 
translocations and epigenetic effects, all of which are poorly detected by the genotyping 
arrays used and to the existence of gene-gene and gene-environment interactions.36 
 
 
2.3.4 Factors influencing the genetic role in disease 
Even if there is an evident strong genetic risk factor in a certain disease, there are many 
ways by which this risk can come across. 
 
 
2.3.4.1 Direct and indirect variations in the DNA code 
As discussed earlier, there are direct changes to the DNA, such as SNPs and copy 
number or copy neutral variations, that can affect a person’s susceptibility for disease.27 
A SNP can lead to various functional changes, e.g. a new or abolished transcription 
factor binding site altering the expression of the gene, a splice variant of a gene 
resulting in distinct functions, structural changes of the protein hindering or enhancing 
the properties of a receptor, etc. These changes on the DNA level are more or less 
irreversible and usually affect all cells in the body, which is very convenient because 
the analysis can be performed on a sample from any tissue in the body, including blood. 
There are also variations that do not directly affect the DNA code, such as epigenetic 
changes. Epigenetic alterations include DNA methylation and histone modification and 
are structural adaptations of chromosomal regions that leave the DNA with a 
“memory”.26 In contrast to direct genetic changes to the DNA, epigenetic changes can 
be modulated both over time and by biological and environmental factors, and be cell 
type specific. Epigenetic alterations can affect the expression of genes, turning them on 
or off.27 
 
 
2.3.4.2 Interactions; gene and environment 
During the last years, it has become clear that neither genes, nor environment act alone 
to cause disease in the context of complex disorders. Genes collaborate with each other 
and with the environment in a complex pattern.39 If a genetic factor functions through a 
complex mechanism that possibly involves several genes and/or environmental factors, 
the associated risk (or protective effect) might remain undetected if a particular gene is 
examined in isolation, as in regular gene-disease association studies (including GWAs). 
Therefore, it is important to take gene-gene (also termed epistasis) and gene-
environment interactions in consideration. Interactions can be defined both functionally 
and statistically. A functional gene-gene interaction is caused by the molecular 
interaction that proteins and other genetic elements have with each other, either in the 
same pathway or in direct complexes.40 A statistical interaction means that the outcome 
(or risk estimated) is different when a particular set of alleles from distinct loci are 
found in combination, than when they are considered apart. The difference is a 
departure from the expected effect if the two alleles were combined independently. The 
departure can be either from an additive model (adding up the effect from each allele) 
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or from a multiplicative model (multiplying the effect from each allele).41 The same 
methods apply when gene-environment interactions are investigated. 
 
 
2.3.4.2.1 
Data supporting gene-gene interactions in complex diseases have emerged rather 
slowly. When searched for, interactions are commonly found, however they are not 
always easy to replicate. The reason might be that disease is due to accumulation and 
interaction of multiple variations acting together in the same network.42 The main 
approach for gene-gene interaction studies performed to date has focused on genes with 
a reported biological or genetic association, in this case to asthma and allergy. A 
successively replicated network is the IL-4/IL-13 pathway, which is central for IgE 
regulation. Several studies have identified the outcome of asthma and allergy to be 
dependent on combinations of variations in IL-4, IL-4Rα, IL13 or STAT6.43-45 IL-13 has 
also been implicated to interact with GATA3, a transcription activator of TH2 cytokines, 
in childhood rhinitis 46 and IL-4Rα and IL-9R have been reported to modify the risk of 
childhood wheezing.47 Other genes, such as TLR2, IL-6, TGFβR2 and FOXP3 
(involved in development and function of regulatory T cells) have also been implicated 
to interact and modify the risk of sensitization against various allergens.48 
 
 
Gene-gene interactions 
2.3.4.2.2 
Gene-environment interactions in asthma and allergy are more frequently reported, 
especially in relation to farming or farm-related exposures. The toll-like receptors 
(TLRs) consist of a family of innate immunity receptors with microbial molecules as 
ligands. The TLR2 gene has been identified as a major determinant of asthma and 
allergy susceptibility in farmers’ children, whereas the TLR4 gene influences atopy in 
children heavily exposed to endotoxins.49 The CD14 gene, a pattern recognition 
receptor for microbial molecules, is dependent on exposure to animals and/or house 
dust endotoxins for its association to asthma, allergy or atopy.50-52 It also modifies the 
protective effect of farm milk consumption on allergic diseases.53 A study investigating 
SNPs in all CD14, TLR2, TLR4 and TLR9 genes identified asthma association to be 
dependent on country living.54 The NOD1 gene is an intracellular pattern-recognition 
receptor that initiates inflammation in response to bacteria and SNPs in NOD1 modifies 
the protective effect of exposure to a farming environment.55 Additional gene-
environment interactions have also been investigated for exposures such as, e.g. air-
pollutants56 and tobacco smoke.57, 58 All these studies have focused on environmental 
interactions with pre-defined asthma and allergy susceptibility genes. A recent large 
scale genome-wide gene-environment interaction study aimed to identify novel 
common gene variations, as well as replicate previously reported findings, however no 
significant interaction was identified.59  
 
 
Gene-environment interactions 
2.3.4.3 Gene expression 
All direct and indirect variation in the DNA mentioned above can alter the RNA 
expression of a gene, which in turn can provide us with clues to the biological 
mechanisms behind genetic alterations. Gene expression can be upregulated, 
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downregulated or abolished. Either the expression of one, or a few genes are 
investigated using smaller scale methodologies, or a more large scale profile using 
expression microarrays (or RNA sequencing) is performed. The large scale approaches 
are valuable tools for identifying key regulatory networks or pathways important for a 
disease, and can also help to define sub-phenotypes within a clinically defined 
phenotype. Integrated with the genetic data on variations in the genome, it can also 
pinpoint individual changes in expression (expression quantitative trait loci, eQTL).60 
Due to e.g. indirect variations in the DNA and external and internal signals to the cell, 
gene expression is cell type specific. Therefore, when it comes to gene expression it is 
very important to consider which tissues or cells should be investigated. Gene 
expression can also be investigated in vitro by e.g. analyzing the downstream effects 
upon modification (overexpression or silencing) of one single gene in a specific cell 
type.  
 
 
2.3.4.3.1 
Variation in gene expression is an important mechanism in mediating susceptibility to 
disease and similar to candidate gene association studies, candidate gene expression 
studies on asthma have been performed. Focusing on differences between severe and 
mild asthma, some studies have reported both altered protein and mRNA expression for 
various inflammatory genes. Increased TNFα (a proinflammatory cytokine) levels have 
been found in bronchoalveolar lavage (BAL), biopsies from the airway lumen61 and in 
peripheral-blood mononuclear cells (PBMCs).62 Along with TNFα, IL33 (a promoter of 
TH2 immunity) gene expression is increased in lung tissues from asthmatic patients.63 
IL-17 (a proinflammatory cytokine) is increased in serum from severe asthmatics 
compared to mild or moderate forms.64 Investigations of global RNA expression in 
blood from asthmatic patients have so far been scarce. A transcriptional profile of T 
lymphocytes from asthmatic children revealed that children from a low socioeconomic 
status (SES) showed overexpression of genes regulating inflammatory processes 
compared to those from a high SES.65 Profiling of subpopulations of PBMCs collected 
from asthmatic children during exacerbation vs. convalescence revealed upregulation of 
TH2-associated functions in monocytes/ dendritic cells during the acute phase.66 
 
 
Gene expression in asthma 
2.3.4.4 Phenotypic heterogeneity 
The phenotype is defined by the observed characteristics of an organism, influenced 
both by the genetic makeup and the environment. In complex disorders, such as 
asthma, the same genotype can result in several different phenotypes. In the same 
manner, different genotypes can give raise to the same phenotype. To be able to 
replicate genetic studies, the definition, measurements and validity of phenotyping need 
to be standardized.67 This makes genetic studies, and especially large scale studies, 
where study groups from several collaborative groups are combined, troublesome. 
Even if guidelines are worked out2, 3 and properly followed, they are often based on the 
phenotypic characteristics and will not take into account the existence of genetically 
different subgroups within the same phenotypic group. This has been shown by cluster 
analysis using 34 different variables on 726 subjects all defined as “severe asthmatics”, 
where not one but five distinct phenotypes were identified.10 Even though large scale 
studies are important to identify over-all important genes, this supports that small scale 
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studies on well defined study groups also are needed to unravel subgroup-specific 
pathways. It also suggests that many of the replication problems of asthma 
susceptibility genes might be due to phenotypic heterogeneity. 
 
 
2.4 GENETICS OF ASTHMA 
It is now commonly accepted that asthma and asthma-related traits behave as typical 
complex disorders. The definition of a complex disorder is: “conditions in which 
various genetic hits that are individually mild may be capable of major phenotypic 
effects, when acting together and within a certain environmental context”. As 
previously discussed there is good evidence that both multiple genes and environmental 
factors are part of the etiology of asthma. 
 
 
2.4.1 Susceptibility genes in asthma 
Over the past years, several susceptibility genes have been identified in asthma and 
allergy-related disorders, both biologically and genetically. The two main genetic 
approaches from start were genome-wide linkage studies and candidate-gene 
association studies, which have become outshined by the GWA studies. Until now, 
there are almost 100 well replicated susceptibility genes in asthma or related traits.68 
Most of the genes have been identified through hypothesis-driven studies where SNPs 
in genes in known pathways are tested against asthma and related phenotypes. Asthma 
susceptibility genes can be categorized into four main groups;  genes associated with 
innate immunity and immunoregulation (e.g. TLRs, NOD 1,2 and HLA-DR-DQ-DP), 
genes associated with adaptive immunity and T helper 2 cell (Th2) differentiation (e.g. 
IL-4,12B, 13,5, IL4,5-RA, GATA 3, TBX21 and STAT6), genes associated with epithelial 
biology and mucosal immunity (e.g. CCL5,11,24,26 and FLG), and genes associated 
with lung function/airway remodelling and disease severity (e.g. ADRB2, GSTP1, 
NOS1, TNF, LTC4S, TNC and NOS1). To these categories one can also add the genes 
identified through positional cloning (e.g. ADAM33, DPP10, PHF11, HLA-G, 
CYPF1P2, IRAKM, COL29A1 and NPSR1).69 The first GWAs on asthma was 
published in 2007, identifying ORMDL370 as a novel susceptibility gene. Since then a 
number of genes have been identified by GWA studies in relation to asthma, including 
CTNNA371, PDE4D72, TLE4 and ChCHD973, DENND1B and CRB174, RAD50, SCG3 
and KIAA127175, HLA-DQ, IL33, IL18R1, SMAD3, GSDMA, IL2RB, RORA, GSDMB, 
IL13 and SLC22A515 (http://www.genome.gov/gwastudies). For many of these genes, 
the function is still uncertain and they might fall under any of the above mentioned 
categories. In the following sections I will discuss some of the asthma susceptibility 
genes examined in this thesis. These have either been primarily identified through 
genetic studies or through their biological properties. 
 
 
2.4.1.1 Neuropeptide S receptor1 
Neuropeptide S receptor 1 (NPSR1 also GPRA or GPR154) is a G protein-coupled 
receptor (GPCR) (see section 2.4.1.3.1), first identified in 2004 as an asthma candidate 
gene through positional cloning.76 The study showed both single SNP and haplotype 
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associations to asthma and total IgE in three separate populations. These findings have 
later been replicated in several studies and populations.77-84 NPSR1 is regarded as one 
of the robustly replicated susceptibility genes for asthma and asthma related traits. 68, 85 
However, it has not, similar to many other previously identified susceptibility genes, 
reached appropriate significance level in any of the performed GWA studies. This 
might be due to poor SNP coverage on the microarrays used, but also due to phenotypic 
variation in the large study groups required for GWA studies. Another possible 
explanation might be gene-gene or gene-environment interactions. Previous studies 
have presented results suggesting that the environment might modify the risk effect of 
NPSR1.77, 78 NPSR1 has, apart from asthma,  also been identified as a candidate gene 
for inflammatory bowel disease86, sleep and circadian phenotypes87 and anxiety88. 
 
 
 
Figure 3. A schematic picture of the NPSR1 gene. The gene is ~220kb and located at chromosome 7p. 
The SNPs used in study I and II are depicted and localised in intron two. Exon 3 harbours the only 
variant, Ile107Asn, that to date has proven to be functionally important. Alternative splicing in exon 9 
result in two gene products, NPSR1-A and NPSR1-B. (Modified from study III) 
 
The NPSR1 gene undergoes alternative splicing and several splice variants have been 
identified, out of which only two, NPSR1-A and NPSR1-B, are transported to the 
plasma membrane.89 These full-length splice variants differ in their 3’ ends with 
alternative terminal exons 9a and 9b (Fig. 3) encoding distinct carboxy-terminal 
peptide chains. What regulates this splicing event is not yet fully understood. The C-
terminus is important for many stages during the lifespan of a GPCR and modifications 
can affect, e.g. transportation to the cell membrane, anchoring, downstream signaling90 
and also potentially dimerization.  
 
Expression of NPSR1 has been identified in e.g. human bronchus, gastro-intestinal 
tract, skin, inflammatory cells76, 89, 91, 92 and in murine brain93. Generally NPSR1-A and 
-B have a similar expression pattern but the A variant is more widely expressed than 
B.91 However there are some discrepancies that might suggest important functionally 
distinct roles for NPSR1-A and -B. In the main, the A variant has a more prominent 
protein expression in smooth muscle whereas the B variant is dominant in the epithelial 
cells.76, 89 The B variant have elevated protein expression in the bronchial smooth 
muscle layer and epithelial cells in asthmatic patients.76 The A variant protein is 
expressed in the basal surface, whereas B is expressed in the apical surface of the colon 
epithelial cells and skin keratinocytes89 and the A variant protein is uniquely expressed 
   15 
in enteroendocrine cells in the gut91. Differences have also been detected in cell lines 
where e.g. a monocytic cell line stimulated with inflammatory mediators showed higher 
mRNA expression of variant B than A.91 However, the expression pattern of NPSR1 is 
still under debate and there are results showing difficulties in detecting expression in 
some of the above mentioned tissues as well.94  
 
The ligand for NPSR1, known as Neuropeptide S (NPS) is a 20-mer peptide. It 
activates signaling through NPSR1 by inducing both Gs and Gq pathways. It was first 
identified in brain and has been shown to regulate functions such as arousal, 
locomotion, food intake and anxiety.93, 95 In general, expression of NPS follows the 
expression pattern of NPSR1.89, 91 
 
Although there are many polymorphisms in NPSR1, only one, a non-synonymous 
variant Asn107Ile, has so far been described to be functionally important (Fig.3). It is 
situated in the first (out of three) extracellular loop. NPS stimulation of the 107Ile 
variant results in increased second messenger response when investigating Ca2+ and 
cAMP accumulation, and MAPK phosphorylation, compared to 107Asn.96-98 
 
 
2.4.1.2 Tenascin C 
Previous expression array studies from our group investigating NPS-NPSR1-A 
signaling identified tenascin C (TNC) as one of the differentially expressed target 
genes.99 TNC is an extracellular matrix (ECM) protein functioning as an adhesion-
modulating molecule. It has its main biological roles in cell communication and signal 
transduction. TNC belongs to a family of glycoproteins that displays highly restricted 
expression patterns but is upregulated in pathological states including inflammation, or 
in reparatory processes such as wound healing.100, 101 Several previous studies have 
connected TNC expression to asthma and allergy both in mouse102-106 and in human107-
112. Genetic studies have so far been scarce. A few genome-wide linkage studies have 
linked the 9q33 region were TNC is situated to asthma or allergic disease and one 
candidate gene study on TNC has been reported, showing strong association to adult 
asthma for a coding SNP (Leu1677Ile). 113-117  
 
  
2.4.1.3 Taste receptor, type 2 
The bitter taste receptor family (TAS2R) consists of more than 25 members. They 
belong to the GPCR family (see section 2.4.1.3.1) and are activated through binding of 
bitter compounds. Some TAS2Rs can respond to several bitter compounds, whereas 
others are activated only by a few. The expression pattern of TAS2Rs has been 
believed to be restricted to the oral cavity, however recent studies suggest gene 
expression and function of the TAS2Rs in the respiratory and gastrointestinal systems. 
In the respiratory system, TAS2Rs are expressed on the motile cilia emerging from 
human airway epithelial cells.118 The motile cilia are important for propelling mucus 
and harmful material out of the lung and previous investigations have shown that viral 
infections and cigarette smoking, which acts as risk factors for asthma, causes a loss of 
airway cilia and might disrupt this defensive system.119 Activation by bitter compounds 
causes an increase in the cilia intracellular Ca2+ concentration and increased ciliary beat 
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frequency.118 Expression of TASR2s has also recently been identified in human airway 
smooth muscle (ASM). Stimulation with bitter tastants causes relaxation of isolated 
ASM and dilation of airways. Inhaled bitter tastants also causes decreased airway 
obstruction in a mouse model of asthma.120 Overall, it seems like TAS2Rs might have a 
protective response effect in asthma. In the gastrointestinal system, TAS2Rs are 
expressed by enteroendocrine cells and are proposed to orchestrate an appropriate 
response to specific nutrients or harmful substances by the release of various peptides 
(reviewed by Sternini et al, 2008).121  
 
 
2.4.1.3.1 
Both NPSR1 and TAS2Rs are G protein-coupled receptors. GPCRs are situated on the 
cell membrane and characterized by an extracellular N-terminus, a seven-
transmembrane α-helix structure spanning the membrane and an intracellular C-
terminus (Fig. 4). Upon extracellular stimulation, conformational changes of the 
receptor cause activation of a guanine nucleotide-binding (G) protein, after which the 
G-protein detaches from the receptor and modulates the activity of other intracellular 
proteins. NPSR1 couples to the G-proteins Gαq and Gαs.93, 95 Gαq causes activation of 
the intracellular protein phospholipase C (PLC), which through a signal cascade causes 
release of intracellular Ca2+. Gαs activates the intracellular cAMP-dependent pathway. 
TAS2Rs couples to the Gα protein, α-gustducin122 which acts similar to Gαq and causes 
intracellular release of Ca2+. However, even if this is regarded as the canonical TAS2R 
signal transduction cascade, there are indications of alternative signaling components as 
well.123 GPCRs can also signal through G-protein independent pathways, such as the 
mitogen activated protein kinase (MAPK) pathway. 124  
 
 
G protein-coupled receptors 
 
 
Figure 4. A schematic picture of a G protein-coupled receptor. When a ligand attaches to the 
extracellular part of cell-membrane spanning GPCR (in grey) the receptor gets activated and the 
intracellular part induces a downstream signal cascade (e.g. cAMP, Ca2+ and MAPK). Many GPCRs are 
glycosylated which can modify the function of the receptor. P indicates phosphorylation sites. 
 
After activation, GPCRs are rapidly desensitized by phosphorylation and arrestin 
binding. It is mainly the serine (S) and threonine (T) residues within the C-termini and 
the third intracellular loop that are responsible for these events.125 After desensitization, 
the receptor is internalized and targeted for degradation, redirected signaling through 
G-protein independent pathways (e.g. MAPK) or recycled back to the membrane.124 
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Phosphorylation site-directed mutations at the C-termini can severely impair both the 
ability to undergo phosphorylation and to recruit arrestin.126, 127 Conformational 
changes improving C-terminal phosphorylation can also enhance arrestin binding and 
endocytosis.128 The NPSR1 variants possesses distinct C-termini where the A variant 
contains five unique phosphorylation sites, and the B variant only two. 
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3 AIMS OF THESIS 
The overall aim with this thesis was to investigate asthma susceptibility genes and their 
genetic role, biological function, as well as how they interact in a context-dependent 
manner, either with other genes or with environmental factors. We also aimed to define 
global gene expression patterns in asthma that could reveal novel insight about 
characteristics of severe therapy-resistant asthma in children. 
 
The specific aims were: 
 
I. To investigate the genetic role of Tenascin C in asthma and allergy and the 
biological and genetic interplay between the two asthma susceptibility 
genes Tenascin C and Neuropeptide S receptor 1. 
 
II. To explore the interactive and biological effects between Neuropeptide S 
receptor 1 and environmental exposures related to farming lifestyle. 
 
III. To examine downstream properties and functional differences between the 
two Neuropeptide S receptor 1 variants A and B. 
 
IV. To identify differences in global patterns of gene expression between severe 
therapy-resistant asthma and controlled asthma in children. 
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4 MATERIALS AND METHODS 
 
4.1 STUDY SUBJECTS AND MATERIALS 
 
4.1.1 PARSIFAL (I, II) 
The cross-sectional PARSIFAL study (Prevention of Allergy, Risk factors for 
Sensitization In children related to Farming and Anthroposophic Lifestyle) includes 
14,893 school children 5 to 13 years from 5 Western European countries (Austria, 
Germany, the Netherlands, Sweden and Switzerland). The PARSIFAL study was 
originally designed to investigate the role of different lifestyles and environmental 
exposures in farm children, Steiner school children, and two corresponding rural and 
urban/suburban reference groups, respectively. The aim was to identify protective 
factors for development of asthma and allergic disorders. In Austria, Germany, the 
Netherlands and Switzerland, the recruitment of children were made at schools in rural 
areas known to have a high percentage of farmers. In Sweden, recruitment was made 
through the Farming Registry at the National Bureau of Statistics. Children with 
anthroposophic lifestyle were collected from Steiner schools and reference groups were 
enrolled from the corresponding geographical areas. The children’s parents completed a 
detailed questionnaire on allergic diseases, infectious history and environmental 
exposures, and blood samples were obtained from the children after informed consent 
from the parents.129 In the present studies (I, II) 3,113 children with available DNA and 
consent for genetic analysis (1,579 boys and 1,534 girls), were included. 
 
The PARSIFAL material has been intensely investigated. The first report concluded 
that growing up on a farm, and leading an anthroposophic life style (to a lesser extent) 
protects from both sensitization and other allergic diseases in children.129 
 
 
4.1.1.1 Group and outcome definitions 
The farm children were defined as children currently living on a farm, and their 
reference group was recruited from children in the same area that did not meet the 
inclusion criteria for the farm children. The Steiner school children were recruited 
among children attending Steiner schools, whose families often act in accordance with 
an anthroposophic lifestyle. Their reference group was recruited from children 
attending other schools in similar suburban/rural areas.  
 
Current rhinoconjunctivitis symptoms were defined as sneezing, runny nose, nasal 
block and itchy eyes in the child during the past 12 months without having a cold at 
the same time. A doctor’s diagnosis of asthma was considered to be present for 
children reporting ever having been diagnosed with asthma, or with obstructive 
bronchitis more than once. Current wheezing was defined as at least one episode of 
wheezing during the past 12 months and current atopic eczema if the child had ever 
had an itchy rash intermittently for at least 6 months and, in addition, reported an 
itchy rash at any time during the past 12 months. Atopic sensitization was defined as 
at least one allergen-specific serum IgE test ≥0.35 kU/L or ≥3.5 kU/L against a 
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mixture of common allergens (Phadiatop®, e.g. pollens, cat, dust mite and mold), 
and/or a mixture of common food allergens (fx5®, e.g. milk, egg, fish and peanut), 
respectively. The term Allergic symptoms was defined by the combination of doctor’s 
diagnosis of asthma and/or current rhinoconjunctivitis. 
 
 
4.1.1.2 Investigated environmental exposures 
The investigated environmental exposures (II) were; ever regular farm animal contact, 
current regular farm animal contact, current regular visits to the barn, mother’s farm 
animal contact during pregnancy, mother worked regularly in stable or barn during 
pregnancy ever consumption of farm milk. Current refers to exposures that occurred 
during the past 12 months, and regular refers to exposures that occurred at least once a 
week. For current regular farm animal contact timing of the initiation of such regular 
exposure was further investigated; current regular contact with initiation in first year of 
life, after first year but more than a year ago, past 12 months, with no current contact 
as reference.   
 
4.1.1.3 Definition of covariates 
The following confounding or potentially confounding factors were included in the 
association and interaction analysis (study I, II): country-of origin 
(Austria/Germany/the Netherlands/Sweden/Switzerland), study group (farm/farm 
reference/Steiner school/Steiner reference), heredity (mother´s or father´s reported 
asthma and/or rhinoconjunctivitis) and gender. 
 
 
4.1.2 Severe Asthma in Sweden (IV) 
The severe asthma study in Sweden is a cross-sectional, observational study on children 
6-18 years of age with problematic severe asthma and their reference group consisting 
of peers with controlled persistent asthma recruited from 14 clinics around Sweden.130 
The aim was to investigate differences between subtypes of asthma by exploring 
heritability, ethnology, patophysiology and clinical presentation. The main inclusion 
criteria to the study were a doctor diagnosis of asthma and daily high or low dose 
administration of inhaled corticosteroids (ICS). The patients were asked to fill out a 
questionnaire and were characterized by spirometry, methacholine provocation, 
measurement of fraction of nitric oxide in exhaled (FENO) and nasal air, and blood 
sampling for inflammatory biomarkers, atopy, DNA and RNA analyzes. Based on the 
clinical characterization the children were categorised to suffer from either problematic 
severe asthma (PA, n=54) or controlled persistent asthma (CA, n=39). Out of 93 
children RNA was sampled from 57 patients. A group of healthy agematched controls 
were also recruited at Astrid Lindgren’s Childrens Hospital, Stockholm. Informed 
consent was obtained from all participating children and their parents. The same team 
of two did all the sample collection and clinical characterization of the patients. 130  
 
Previous results from the study report that children with PA more often had parents 
with asthma, came from families with a lower socioeconomic status, were less 
physically active and had more comorbidity with rhinoconjunctivitis than children with 
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CA. Children with PA also exhibited lower FEV1 values and increased bronchial hyper-
responsiveness compared to children with CA.130 
 
 
4.1.2.1 Outcome definitions 
For gene expression analysis patients defined as severe asthmatics (SA) were recruited 
from the group of problematic severe asthma patients (PA), that were resistant to 
therapy and not exposed to pets in the household, smoking or other aggravating factors 
(n=20). Controlled asthmatics (CA) were recruited from the controlled, persistent 
asthma group (n=20), and healthy controls (ctrl) (n=19) were used as a reference group. 
The most severely affected patients from the SA (less than 19 points) and the least 
severely affected patients from the CA group (more than 20 and less than 24 points) 
were selected based on the self-reported asthma control using the Asthma Control 
Test® (ACT) score.131, 132  
 
 
4.1.3 Cells and cell lines (I, II, III, IV) 
Various cells and cell lines have been used to enable in vitro and in vivo studies. In 
study I and III, we primarily worked with NPSR1 overexpressing cells due to the 
relatively low endogenous expression of NPSR1 in most cell lines. The foremost cell 
line for NPSR1 overexpressing studies have been the human embryonic kidney cells 
(HEK293). The HEK293 cells have been either stably expressing NPSR1-A (I) or 
transiently transfected with NPSR1-A or -B (III). The vector used is under a pCMV 
promoter89 and both NPSR1-A and -B constructs harbour the more potent 107Ile 
isoform.96 For replication and verification of results seen in the HEK293 cells NPSR1-
A or -B transiently transfected human epithelial lung carcinoma cells (A549) and 
human neuroblastoma cells (SH-SY5Y) were used (III). In the experiments, NPSR1 
overexpressing cells were stimulated with NPS, the ligand for NPSR1, for a pre-
defined time and the results obtained by comparing the stimulated cells against the non-
stimulated control cells (I, III). 
 
Freshly drawn peripheral whole blood was used for study II and IV. In study II NPSR1-
A and -B expression was investigated before and after lipopolysaccharide (LPS) 
stimulation (a proxy for farm animal exposure) of monocytes from healthy donors. In 
study IV, whole white blood cells from asthmatic patients and healthy controls were 
freshly obtained and immediately stored in RNAlater® until RNA extraction and later 
used for genome-wide RNA expression analysis. 
 
 
4.2 GENETIC ANALYSIS 
 
4.2.1 Genotyping (I) 
DNA for all genotyping in the PARSIFAL samples was extracted from whole blood 
(Sweden, Switzerland, and the Netherlands), or from buffered white blood cells 
(Germany and Austria) using Qiagen kits. When performing genotyping, there is a 
choice ranging from a targeted small-scale approach up to a whole-genome large-scale 
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approach. If a low number of SNPs are to be investigated, that can be easily achieved 
by TaqMan® SNP genotyping assays where one or a few SNP are analyzed at the time. 
For whole-genome genotyping, the SNP genotyping arrays discussed earlier can be 
used. For an intermediate number of SNPs (e.g. >10) to be analyzed, we used MALDI-
TOF mass spectrometry (matrix-assisted laser desorption/ionization-time of flight; 
Sequenom GmbH) (I, II). Using this technology, primer sequences for 25-30 SNPs can 
be pooled and analyzed at the same time in one sample. In study I, twelve SNPs in 
TNC, tagging the 50% of the most 3’ 50 kb of the gene (Fig. 5) were successively 
genotyped. Seven SNPs tagging a haplotype block in NPSR1 (Fig. 3) 76 had previously 
been genotyped in PARSIFAL 80 and were also used for downstream applications in 
these studies (I, II).  
 
 
4.2.2 Association analysis (I) 
Allelic association was analyzed in cases versus controls in the PARSIFAL material (I) 
using χ2-test in Haploview 3.2133. Odds Ratios (OR) and 95% Confidence Intervals (CI) 
were calculated. Block-wise inheritance (haplotypes) was estimated using the LD 
measure D’ in Haploview defined by Gabriel et al.134 Haplotype association was tested 
in the statistical software ‘R’ (http://www.R-project.org) using the haplo.score 
algorithm implemented in the haplo.stats package. A permutation test was used to 
correct for multiple testing, and adjustment for the covariates; country-of origin, 
sampling group, and gender was performed on the haplotype analysis. 
 
 
4.2.3 Interaction analysis (I, II) 
Interaction analyses were performed in the PARSIFAL material both between genes 
(I), gene-gene interaction, and between gene and environmental exposures (II), gene-
environmental interaction. This was done to investigate if the risk effect of one variable 
is dependent on the other. A multiple logistic regression model was used to test for 
interactions by adding an interaction term between the genotypes, or genotype and the 
environmental exposure investigated. P-values for departure from a multiplicative 
interaction model on the OR scale were obtained by likelihood-ratio tests between the 
models with and without interaction term. Permutation tests were used to estimate a 
global empirical p-value for interaction (see 4.5.1). The final regression models were 
adjusted for the confounders, or potential confounders; gender, study group, country-
of-origin (I) and heredity (II).  
 
 
4.3 RNA EXPRESSION ANALYSIS 
When RNA expression is investigated, the extracted RNA molecules are used as 
templates for reverse transcription and the synthesizing of complementary DNA 
(cDNA) or RNA (cRNA). The cDNA or cRNA molecules are targeted by primers 
and/or hybridized to probes and the number of molecules measured by fluorescence 
intensity.    
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4.3.1 Expression arrays (III, IV) 
To investigate global gene expression, we applied microarray technology. On the 
microarray, a number of DNA probes for each gene are spotted, labeled cDNA (Gene 
ST 1.0) or cRNA (HGU133plus2) are hybridized to the probes and fluorescence 
intensity measured. For transiently NPSR1-A or -B overexpressing HEK293 cells 
stimulated with NPS (III), the Affymetrix HGU133plus2 expression array was used. 
These arrays primarily tag the expression of the 3’ end of the genes. When we 
investigated differential gene expression in white blood cells from severe asthmatics, 
controlled asthmatics and healthy controls (study IV), the Affymetrix Human Gene ST 
1.0 expression array was used. These arrays are newer and give a more complete 
coverage of the whole transcriptome. Hybridizations and scannings were carried out 
using standard protocols for gene expression (www.affymetrix.com). Pre-processing 
and normalization of the data was performed using the statistical software ‘R’ by 
implementing relevant packages from Bioconductor (http://www.bioconductor.org) and 
KTH (http://www.biotech.kth.se/molbio/microarray). Six hybridizations were 
performed in study III, two technical replicates each of NPS-NPSR1-A, NPS-NPSR1-B 
and NPS-HEK293/empty vector. In study IV, 59 hybridizations were performed (20 
SA, 20 CA and 19 Ctrls). After normalization and quality control, five samples were 
excluded as outliers, resulting in data for 17 SA, 19 CA and 18 Ctrls used in 
downstream analysis. 
 
To assess differentially expressed genes, two different approaches were used. For the 
NPSR1-A or -B overexpressing cells (III), a t-test statistics, comparing the contrasts; 
NPS-NPSR1-A vs. NPS- HEK293/empty vector and NPS-NPSR1-B vs. 
HEK293/empty vector, were used with a B-value > 7 as cut-off for significantly 
differentially expressed genes. The B-statistics is the log-odds that the gene is 
differentially expressed and a B value of 7 corresponds to a probability of 99.99% that 
the gene is differentially expressed. Gene lists were generated for differentially 
expressed genes in NPSR1-A and -B separately. When we investigated differentially 
expressed genes in WBC from asthmatics (IV) an F-statistics as a global test (combines 
the t-statistics for all contrasts into an overall test of significance for that gene) was 
used to identify differentially expressed genes in any of the contrasts; MA-Ctrl, SA-
MA, SA-Ctrl. The t-statistics were then used to reveal the contribution of each contrast 
to the global test and an adjusted p-value ≤ 0.05 was regarded as significant. 
 
The enrichment analyses (IV) were assessed using the DAVID 6.7 database 
(http://david.abcc.ncifcrf.gov).135, 136 Enrichment implies that there is a significantly 
larger amount of genes forming e.g a pathway in your data set than you would expect 
by chance. In this study, enrichment was considered significant if the adjusted p-value 
was ≤ 0.05 relative to the affymetrix Human Gene ST 1.0 background. Both 
enrichment for predefined pathways and enriched biological processes were 
investigated. 
 
 
4.3.2 Quantitative real-time polymerase chain reaction (I, II, III) 
To investigate differential gene expression in a more targeted approach, we used 
quantitative Real-Time Polymerase Chain Reaction (qRT-PCR). qRT-PCR was 
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performed on both NPS stimulated NPSR1 overexpressing cells (I, III) and LPS 
stimulated fresh monocytes (II). The genes targeted for qRT-PCR included both the 
expression of NPSR1 itself (II, III) and a selected group of NPS-NPSR1 downstream 
genes (I, III). When running qRT-PCR, you have an option of a primer-probe-primer 
combination or a primer-primer combination. The lack of a probe decreases the 
specificity but increases the sensitivity. Throughout study I, II and III, a primer-primer 
combination was used applying SYBR® Green chemistry and the PCR was run on a 
7500 Fast Real-Time PCR system (Applied Biosystems). Relative quantification and 
calculation of the range of confidence was performed with the comparative ∆∆CT 
method.137 To statistically verify differential gene expression, the paired Wilcoxon 
signed rank test (II) or Student’s t-test (III) was used.  
 
 
4.4 FUNCTIONAL ANALYSIS (I, II, III) 
A selection of functional analyses has been performed to generate hypotheses for, 
strengthen, or verify the genetic findings. Immunohistochemistry (IHC) with antibodies 
targeting NPSR1-B and TNC was used (I) to identify the localization, and potential co-
localization of the two proteins in bronchial biopsies from asthmatic patients and 
healthy controls. Fluorescence-based quantification, flow cytometry, with antibodies 
targeting NPSR1-A or NPSR1-B (II) or a common antibody targeting the N-terminal of 
both NPSR1 isoforms (III) was used to determine the NPSR1protein expression on the 
cell membrane w/wo NPS (III) or LPS (II) stimulation. Upon stimulation of GPCRs 
there is an accumulation of intracellular second messengers such as cAMP and Ca2+. To 
measure cAMP accumulation after NPS stimulation of NPSR1-A or -B overexpressing 
cells, an enzyme immune assay was used. To measure the Ca2+ accumulation, cells 
were loaded with Fluo-4 NW and the increased fluorescence measured (III). Activation 
of transcription factors was investigated by a reporter assay for the three signaling 
pathways; cAMP/PKA, MAPK/JNK and MAPK/ERK, in which the relative luciferase 
activity was assayed. We also applied phosphorylation site-directed mutagenesis on the 
C-termini of NPSR1-A and -B to test if differences in signaling properties were due to 
dissimilar number of phosphorylation sites in the C-terminus. Serine (S) and threonine 
(T) residues were exchanged for a neutral alanine (A). These modified construct were 
then used for transient transfection and qRT-PCR as described in section 4.3.2. 
 
 
4.5 STATISTICS 
 
4.5.1 Multiple testing 
Generally, the more tests that you run, the greater are the chances that false positives 
will be included as significant observations. A false positive (type I error) is when a 
result will appear as significant without any true effect. To control for type I errors, one 
can use various forms of multiple testing corrections. 
 
This phenomenon was mentioned briefly in section 2.3.3.4 on GWA studies, where a 
huge number of tests are performed. However, it is also important to consider multiple 
testing when performing regular case-control association studies, as well as interaction 
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studies, since it will guide you on how true your positive findings are. The multiple 
testing problems in GWA studies are usually approached by a Bonferroni correction, 
where the significance level of 0.05 is divided by the number of tests performed. This is 
a very conservative approach and might disregard true positives (false negative, or type 
II error). In study I and II we instead used permutation tests to correct for multiple 
testing. A permutation test (also called a randomization test) treats the genotypes or 
haplotypes as fixed, while the disease association status (cases or controls) is 
randomized. This provides each individual with a new affection status. A number (e.g. 
>1000) of randomized association tests are executed and the proportion where a 
stronger association is found there than in the actual data provides the empirical p-value 
of the observation. This is done in a similar way for interactions. 
 
In the genome-wide array expression analysis (study III, IV), a Benjamini Hochberg 
(BH) test was used for multiple testing correction, both to detect differentially 
expressed genes and to identify significantly enriched pathways when performing gene 
enrichment analysis. The BH method aims to control for false discovery rate (FDR) 
which is defined as the ratio between expected false positives to the total number of 
significant results. After correction, a new adjusted p-value can be provided.  
 
 
4.5.2 Population structure 
Population stratification is defined as a biased mixture in the genetic background of a 
population.138 That is, if cases are collected from one geographic region and controls 
from another, the allele frequency of the investigated SNP might be different depending 
on the geographic region, rather than true difference between cases and controls. The 
“region” usually refers to different countries but this phenomenon can also occur within 
a country if little mixture between the people has occurred. The consequence of 
population stratification is identification of false positives. There are also other factors 
(e.g. gender, age) that can potentially bias the result in a similar way, i.e. the results are 
not a consequence of what you investigate but due to an underlying factor. All these 
factors can be included in models used for analyzing the data and thus attempted to be 
corrected for (I, II). 
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5 RESULTS AND DISCUSSION 
 
5.1 ASSOCIATIONS (I) 
An association study compares the frequency of alleles in controls and cases. A 
significant single SNP association takes place when one allele has an altered frequency 
in cases compared to controls. The corresponding allele is then referred to as a risk (or 
protective) allele. Haplotypes are investigated in a similar manner. 
 
In study I we investigated TNC association to childhood allergy- and asthma-related 
traits by genotyping 12 SNPs in the PARSIFAL material. The whole ~100kb TNC gene 
splits up in two large LD blocks and the SNPs were picked to tag the most 3’ LD block 
(~50kb) which previously had shown to be associated to asthma. 117 Figure 5 illustrates 
the LD block composed of the genotyped TNC SNPs and their relative position in the 
gene. Association was detected between several of the SNPs in TNC to current 
rhinoconjunctivitis, with the most significant associations to SNP rs3789873 (p=0.002). 
Weaker associations were seen for phenotypes such as doctor’s diagnosis of asthma 
and atopic sensitization. Haplotype analysis revealed three blocks, as defined by 
Gabriel et al134, with block 1 showing the strongest association to current 
rhinoconjunctivitis (p=0.0005). These results indicate that TNC, previously thought of 
mainly as a biomarker for asthma and inflammation107-112, and with limited genetic 
studies in asthma and allergy related disorders117, also is genetically associated to 
childhood rhinoconjunctivitis. However, rather than one causative SNP, there seemed 
to be many SNPs all contributing with smaller effects to the risk of disease. This might 
also be a consequence of the tight LD between the SNPs. 
 
 
Figure 5. An LD plot assembled by the 12 TNC SNPs genotyped in the PARSIFAL study group. The LD 
plot, as defined by Gabriel et al 134, divides TNC in three haplotype blocks 1, 2 and 3.The numbers in 
each box correspond to the pair-wise linkage disequilibrium (LD) coefficient D’ between SNPs, given in 
percentage. A D’=1 (indicated here by an empty square) indicates that no recombination has occurred 
and a D’ of <1 indicates that recombination has occurred. (From study I). 
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As for all genetic analyzes, it is always important to have clearly defined groups of 
healthy and affected idividuals. Since the PARSIFAL material is designed as a cross-
sectional epidemiological study and not a case-control material in the proper sense, it 
might not be optimal for gene association (or gene interaction analysis, see section 5.2). 
The cases are much fewer than the controls and when investigating one outcome as 
cases there might be a mixture of the other outcomes in the controls. This lack of “clean 
controls” might lead to false negative results. For some outcomes, we attempted to 
remove those control subjects with closely related allergic phenotypes. However, due to 
loss of power there were no dramatic changes in the results. Nevertheless, the main risk 
of having mixed control groups is that we fail to identify true associations or 
interactions (false negatives), rather than identifying false positive association. 
 
Many of the small genetic association studies that have been performed to date are now 
outshined by large-scale GWA studies. A massive number of patients and controls 
(sometimes more than 25, 000) 15 are recruited, often a fusion of already collected case-
control materials. This is a very powerful tool to identify novel genes that are thought 
to have an overall large impact on the disease. However, if designed in a proper way, 
there are some advantages for the small scale candidate studies still. In large scale 
studies, it is challenging to have a universal classification of the phenotypes. Even 
though proper guidelines are utilized, a doctor´s diagnosis of asthma defined by one 
clinician might not be the same as a doctor´s diagnosis of asthma defined by another. 
Fusing these materials might thus lead to dilution of the genetic effects impacting each 
sub-phenotype. In small scale studies the phenotypic characteristics might be more 
homogenous enabling to identify genes with a specific role in a specific subtype of 
allergic diseases. Large scale studies also make it more cumbersome to pursue with 
investigating small genetic effects, which in combination with other small genetics 
effect or environmental factors might lead to an interactive increased risk effect. 
  
 
5.2 INTERACTIONS (I, II) 
Gene-gene or gene-environment interactions take place if the risk effect of one outcome 
(gene or environment) is dependent on the other outcome (gene or environment). That 
is, the risk (or protective) effect of the combination of two genes is significantly higher 
than simply adding, or multiplying those two risk effects up. In this thesis (study I and 
II) we have used a multiplicative model to test for interaction and investigated a 
departure from the odds ratio (OR) scale. A likelihood ratio test (LRT) was then used to 
compare the models with and without interaction terms and to test the null hypothesis 
of no interaction. The gained p-value indicates whether the effect (OR) of one genotype 
is altered by the effect of another genotype or environmental exposure. 
 
As both NPSR1 and TNC have been implicated as risk factors for asthma, and since 
TNC is regulated by NPS-NPSR1 activation99, we aimed to explore the risk 
modification, or gene-gene interaction, between TNC and NPSR1 in the PARSIFAL 
material (study I). We analyzed the 12 SNPs genotyped in TNC and 7 NPSR1 SNPs 
previously genotyped and moderately associated with asthma and atopic sensitization 
in PARSIFAL.80 The results showed that several significant interactions were taking 
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place between the TNC and NPSR1 in subjects with atopic sensitization or doctor’s 
diagnosis of asthma. The most significant interaction was seen between TNC 
rs3789873 and NPSR1 rs324377 (p=0.002). However, there was no combination of 
SNPs that seemed to have a greater impact over the risk modification than the other 
combinations. The interaction analysis indicated that, depending on the NPSR1 
genotype, TNC variants can be associated with both an increased and a decreased risk 
of disease, and that several TNC*NPSR1 SNP combinations can lead to similar risk 
modification. Interestingly, the interactive effects between the two genes were not seen 
in phenotypes were TNC by itself had a strong main effect (e.g. rhinoconjunctivitis). If 
a strong main effect is seen by one gene it might be less likely to be altered by another 
gene in that specific setting. 
 
Previous studies on NPSR1 have presented results suggesting that some of the 
conflicting association studies might be due to gene-environmental interactions.77, 78 
Since the PARSIFAL material has a wealth of information about environmental 
exposures related to farming lifestyle, we used the 7 NPSR1 SNPs genotyped in 
PARSIFAL80 to investigate potential gene-environmental interaction (study II). 
Farming is believed to be a protective environmental factor for the development of 
asthma and allergic disease, especially if exposure takes place during pregnancy or 
early life, involves contact with multiple animal species, and is combined with 
consumption of farm milk.129, 139-145 In study II, we assessed whether the protective 
effects of farm related exposures was influenced by NPSR1. The protective effects of 
regular farm contact, current regular visit to the barn, mother’s farm animal contact 
during pregnancy, mother worked regularly in stable or barn during pregnancy and 
ever consumption of farm milk were tested. When analyzing the combined phenotype 
allergic symptoms strong effect modification was seen for current regular farm animal 
contact especially by SNP rs323922 (p=0.001) and rs324377 (p=0.002). The protective 
effects of the other variables against development of allergic symptoms were not 
dependent on genotype. When investigating the effect of the timing of current regular 
farm animal contact there was a tendency towards a protective effect, regardless of 
genotype, if contact was initiated during the first year of life. However, if the contact 
was initiated after early infancy, the environmental effect differed considerably 
depending on the NPSR1 background (Fig. 6). 
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Figure 6. The effect of current regular farm animal contact on allergic symptoms is dependent on NPSR1 
genotypes in the PARSIFAL children. Being homozygote for AA at rs324377 gives a protective effect 
against allergic symptoms, when current regular farm contact was initiated within last twelve months. 
Global p-value for interaction, p=0.003. All groups are compared to the reference group that has no 
current farm animal contact. (From study II). 
 
 
These results show that the effect of environment can differ depending on the genetic 
background. They also propose that when a strong protective effect from the 
environment already exists, as the documented protective effect of farm animal contact 
during pregnancy and early infancy, genotype interaction might have less effect. Later 
in life, when the environmental effect is not as dominant, the interplay with genetic 
factors becomes more important for the total outcome. Which is the same phenomenon 
as we observed in the TNC and NPSR1 interaction analysis. 
 
Both these studies highlight the importance of taking interactions into account when 
performing genetic or epidemiological studies. They also show that the results are not 
always straight forward to interpret. A risk genotype can be reversed to a non-risk 
genotype depending on the combination with another genotype in another gene. When 
interpreting the effect of the interaction (e.g. are the combinations of genotypes leading 
to risk or protective effect) the effect is also always mirrored to what you compare to, 
i.e. the baseline. The phenomenon of risk effects being reversed has been described as 
the flip-flop phenomenon 146 and discussed in the sense that many replication studies 
can replicate an association for a SNP, but in one population one allele is associated to 
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risk and in another population, the other allele. A possible explanation for this could be 
interactions both with other genes and environmental factors.  
 
Even if interaction studies are very important in resolving the complex inheritance 
pattern, random interaction analysis will result in vast problems with multiple testing. 
In study I and II we evaluated already identified risk-modifying genes and genes with 
known or suspected biological or environmental interactions. This approach results in 
fewer tests and may be a more trustworthy finding since there is a relevant hypothesis 
behind the test. It is also a good approach to start with, even though the scope of 
novelty might be restricted. Even if the analyses are supported by a hypothesis, 
interaction analyses can still be troublesome. Due to the many different combinations 
investigated, relatively large materials are needed to have enough statistical power. For 
example, when a gene-gene interaction analysis is performed there will be 9 different 
genotype combinations (Table 1).  
 
Table 1. Illustrating the possible combinations for a gene-gene 
interaction 
 Gene 1 
Gene 2 Common HoZ HeZ Rare HoZ 
Common HoZ 1 2 3 
HeZ 4 5 6 
Rare HoZ 7 8 9 
HoZ; homozygote, HeZ; heterozygote 
  
To be able to compare all possible combinations, all boxes must be filled with subjects 
carrying the specific combination of genotypes in gene 1 and gene 2. This might be 
easily achieved when common SNPs with high minor allele frequencies are used, but 
when rare alleles are investigated, box no 9 might not be easy to fill unless the number 
of study subjects is large. In study I and II, the power problem was addressed by 
combining phenotypes (e.g. allergic symptoms defined by the combination of doctor’s 
diagnosis of asthma and/or current rhinoconjunctivitis) or genotypes, e.g. 
heterozygotes (HeZ) and rare homozygotes (HoZ) were in some cases combined to 
one outcome. Larger study groups to increase the power are necessary, but have to be 
approached with care. With larger study groups follows less homogenous phenotypes 
and instead of increased power we end up with less power to detect the specific 
interactive effects that might cause one specific subtype of asthma. This may be the 
reason why genome-wide interaction studies have not been very successful so far.59 
 
Interactions do not only occur between genes or between gene and environment, but 
can also take place within a gene, intragenic interaction (Orsmark Pietras et al, 
unpublished data). NPSR1 is a relatively large gene (~220kb), which splits up in several 
LD blocks. The size of the gene makes it likely that the blocks are inherited 
independently of each other. This opens up for the possibility that when risk SNPs 
located in different LD blocks are inherited together on the same allele, they might 
interact and give a joint risk effect. Unpublished data show that this phenomenon 
occurs in NPSR1 (Orsmark Pietras et al, unpublished data). This might be a possible 
explanation to why NPSR1 is very often identified as an asthma and allergy 
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susceptibility gene76-84, but no causative SNP has been identified yet. Possibly, many 
SNPs with a moderate risk effect (that might not always show up as significant in 
association studies) act together to give a joint risk effect. 
 
In study I and II we only investigated interactions between two factors (gene-gene or 
gene-environment). An issue that needs to be addressed is that in complex diseases 
there are probably multiple factors (many genes and many environmental factors) that 
interact. All these interactive effects might be one possible explanation for the “missing 
heritability” described earlier. It is possible that many small changes within the same 
gene or pathway (gene-gene, gene-environment, epigenetics) might act together and 
result in the same phenotypic characteristics e.g. asthma. These alterations do not 
necessarily have to be the same in each individual, hence confusing genetic analyses. 
 
 
5.3 GENE EXPRESSION (I, II, III, IV) 
To investigate the function of a gene, one can assess its RNA expression, i.e. identify 
where in the body the gene is expressed and how the expression of a gene alters upon 
various stimuli, changed conditions or disease states. This can be performed in vivo by 
investigating the expression in freshly sampled cells and tissue, or in vitro by 
manipulating cells in culture. There are several approaches to analyze RNA expression; 
either the expression of the gene itself is investigated, or the downstream effects that 
the gene of interest is causing. In this thesis, expression arrays (Affymetrix) have been 
used to detect global expression patterns (study III and IV) and qRT-PCR have been 
used for a more targeted gene-by-gene approach (study I, II, III). 
 
In study I and III, NPSR1 overexpressing cells grown in culture were used to 
investigate the downstream effect of NPS stimulation. Global gene expression patterns 
downstream NPS stimulation of NPSR1 receptor variant A signaling has previously 
been assessed by microarray analyzes on NPSR1-A stably overexpressing HEK293 
cells.99 The study identified “cell proliferation”, “morphogenesis” and “immune 
response” as the most enriched biological processes. One of the target genes, showing a 
≥ 4-fold upregulation, was Tenascin C (TNC). In study I we investigated this regulation 
further and identified a dose-dependency between increased TNC expression and 
increased doses of NPS (0.1, 1 and 5µM). This implies a biological relationship 
between NPSR1 and TNC which lead us to further investigate the genetic interactions 
described earlier in this thesis (see 5.2). In study III, we investigated potential 
differences in downstream gene expression between the two NPSR1 variants A and  B. 
HEK293 cells transiently overexpressing NPSR1-A or -B were stimulated with NPS 
and global gene expression assessed using microarray technology (Fig. 7 a).  
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Figure 7. Gene expression measured downstream NPS stimulation of transiently NPSR1-A or NPSR1-B 
overexpressing HEK293 cells. (a) NPSR1-A and -B differentially expressed genes as assessed using 
affymetrix expression-arrays revealed 66 genes induced by the -A isoform (cut off = ≥2 fold), of which 44 
were induced by -B. (b) qRT-PCR verification showing relative expression of CGA, CD69 and NTS after 
NPS-NPSR1 concentration- and time-response experiments. Data shown as means relative to an NPS 
stimulated empty vector control ± SEM. * indicates at which concentrations or time points the difference 
between NPSR1-A and -B was significant (p ≤ 0.05). (From study III). 
 
The results demonstrated that both receptor variants in principal regulated the same set 
of genes, but that genes regulated by variant A constantly were induced to a higher 
degree. This was verified by qRT-PCR on 11 genes from the array experiment, where 
we further investigated both dose (1nM-10µM) (represented by CGA, CD69 and NTS 
in Fig. 7a, c, e) and time (0.5-48h) (represented by CGA, CD69 and NTS in Fig. 7b, d, 
f) dependency of NPS stimulation. The only notable exception was CD69 (Fig. 7c, d), 
which was induced to a higher degree by receptor variant B. CD69 is an early activator 
of regulatory T cells (Tregs), which are important in monitoring the balance between 
TH1 cells and TH2 cells. Recently, CD69 was reported to specifically control the 
pathogenesis of allergic airway inflammation.147 The expression of the 11 genes from 
the array experiment was also investigated in two additional NPSR1-A or -B 
overexpressing cell lines, a lung cell line (A549) and a neuroblastoma cell line (SH-
SY5Y). The results showed a similar trend, i.e. receptor variant A was a stronger 
inducer of gene expression, in these cells as well. Since these two isoforms have been 
shown to have explicit roles in asthma and allergy76, 86, 89, 91, 92, these results might 
provide an isoform-specific link to pathogenetic processes in allergic airways (more 
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data on the differences between the two receptor variants are presented and discussed in 
section 5.4) 
 
In study II, NPSR1 RNA expression was investigated, using qRT-PCR, in freshly 
obtained human monocytes cultured and stimulated for 6h and 24h with or without 
LPS, a potential proxy for farm animal exposure. The monocytes, derived from 10 
healthy blood donors showed a modest trend towards upregulation of NPSR1-A and -B 
(however less for B) mRNA expression after 6h of LPS stimulation. 
 
Since most genes have a distinct expression pattern in different cells, and the 
expression is regulated by a number of factors unique for that cell, it is difficult to 
decide what the proper cell types for investigations are. When assessing effects 
downstream NPS-NPSR1 signaling we have often used the HEK293 cell line (study I, 
III). It has the advantage of being a fast growing and easily transfected cell line. 
Previous studies on the NPS-NPSR1 system have also utilized HEK293 cells which 
makes the results easier to compare. However, one should be aware of that results 
obtained from one cell line might not be representative to other cells, or in vivo. This is 
why it is important to investigate several different cell lines (as in study III when we 
confirmed the results obtained by experiments in HEK293, in A549 and SH-SY5Y 
cells). In study II, we investigated how the expression of NPSR1 changed in monocytes 
upon LPS stimulation. Even if the choice of cell type is well motivated, as in study II 
when NPSR1 expression previously had been identified in monocytes 148, it is difficult 
to decide beforehand what the proper cells or tissues for investigation are. The assumed 
function of a gene might not always be the same as the true function. In addition, a 
gene can have different function in different settings. The solution, if there is one, 
might be to perform the experiments in many different cells and tissues and at different 
conditions. 
 
In study IV, we investigated global gene expression in whole white blood cells (WBCs) 
obtained from healthy controls (Ctrl, n=18), children with persistent but controlled 
asthma (CA, n=19) and children with severe therapy resistant asthma (SA, n=17). The 
aim was to elucidate if there were differences in gene expression between subgroups of 
asthma. We identified 1378 genes that were differentially expressed (DE) in any of the 
comparisons CA-Ctrl, SA-CA and SA-Ctrl, with 355 genes exclusively DE in SA 
compared to both Ctrl and CA. In an attempt to control for the possibility that 
differences in expression not was due to differences in cell count between the groups 
(since WBCs were used), eosinophils and neutrophils were compared, and no 
significant difference in cell count was detected between SA and CA. We also 
investigated differences in other clinical characterization between the SA and CA 
groups used in this study (which were a selection of patients from the original study).130 
Apart from differences seen in asthma control score test (lower in SA) and dose of 
inhaled corticosteroid (higher in SA), which were the inclusion criteria for expression 
analysis, a significant differences was seen for methacholine responsiveness 
(DRSmethacholine , slope of the dose-respons curve for provocation with methacholine) 
(higher in SA, p=0.04). There were no significant differences seen for FEV1 (forced 
expiratory volume during 1s), total WBC (white blood cells), FENO (fraction of nitric 
oxide in exhaled air) or total IgE. 
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To elucidate how homogenous the expression of these genes was in the pre-defined 
groups; Ctrl, CA and SA, we performed unsupervised hierarchical clustering and 
generated a heatmap of the 1378 DE genes (Fig. 8). The cluster analysis did not reveal 
three perfect column dendogram clusters, but rather illustrates that although extensively 
clinically characterized patients, there are some overlaps between the groups when it 
comes to gene expression. Previous cluster analysis with several different categories, 
such as phenotype and clinical testing parameters, show that we need to take a number 
of parameters into consideration in order to achieve the well-characterized subgroups of 
asthma that are needed to identify genetic risk factors.10 The row clusters in the 
heatmap nicely show the pattern of up- or down-regulated genes in each subject. 
 
 
 
 
 
Figure 8. Global gene expression patterns in asthma patients and healthy controls. Unsupervised 
hierarchical clustering and heat map illustrates each individual’s expression pattern in all 1378 
significant (p ≤ 0.05) differentially expressed genes.  Normalized gene expression is indicated by the row 
Z-score where yellow-red represents up- and blue down-regulated genes. SA, severe asthma; CA, 
controlled asthma; Ctrl, healthy controls. (From study IV). 
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After identifying genes that could tell the groups apart, we performed gene enrichment 
analysis to investigate biologically relevant groups and pathways that were significantly 
enriched among these genes.  Three pathways were identified; Bitter taste transduction 
(upregulated mostly in SA), Natural killer cell mediated cytotoxicity (mostly 
upregulated in CA) and N-Glycan biosynthesis (downregulated in SA).  
 
The bitter taste receptor family (TAS2Rs) has recently been linked to a protective role 
in asthma pathogenesis. Expression of TAS2Rs has been identified on the motile cilia 
of human airway epithelial cells where stimulation with bitter compounds increases the 
ciliary beat frequency and enables a more efficient clearance of e.g. mucus out of the 
lung.118 TAS2Rs have also been identified in human airway smooth muscle (ASM) 
where bitter tastants caused relaxation of isolated ASM and dilation of airways. Inhaled 
bitter tastants also caused decreased airway obstruction in a mouse model of asthma.120 
TAS2Rs have however not been connected to asthma and allergy outside the airway 
system. Here, we report upregulation of TAS2Rs in human white blood cells in patients 
suffering from asthma. The detailed role of taste receptors expressed in peripheral 
blood cells, however, warrants further investigation. Intriguingly, the upregulation of 
TAS2Rs was mostly seen in the severe therapy resistant asthmatics and this underlines 
the need for additional studies in order to better understand the mechanisms behind 
therapy-resistant asthma.  
 
Natural killer (NK) cells are a type of cytotoxic lymphocytes that cause the target cell 
to die by apoptosis. Their role in asthma has been debated and studies have both shown 
a vast upregulation of NK T-cells in bronchoalveolar-lavage fluid from asthmatic 
patients 149, as well as no increase at all.150 Murine models have supported the role of 
NK T-cells in asthma by showing that NK T-cell deficient mice do not develop, or 
showed impaired, allergen-induced airway hyperreactivity.151, 152 Our results point 
towards a role for NK T-cells in asthma.  
 
The N-glycanbiosynthesis pathway is responsible for the making of glycans that 
couples to proteins and lipids on the cell membrane. Glycosylation is one of the most 
common post-translational modifications, and almost half of all proteins are 
glycosylated.153 Glycosylation patterns change extensively with T cell development and 
differentiation and recent data also states that these changes play a powerful role in 
regulating T cell responses.154 It has been suggested that alterations in the distribution 
of glycoproteins at the cell surface contributes to many chronic human diseases, 
including autoimmunity.155 Of note, NPSR1 and TAS2Rs both display N-glycosylation 
which is involved in trafficking of the receptor to the cell surface, and functioning of 
the receptor once attached in the cell membrane. For TAS2Rs, N-glycosylation has 
been reported to play a role in the maturation of the receptors, but is has been 
implicated that the N-glycan pattern does not have a major impact on the function of 
either NPSR1 or the TA2SRs.156, 157 
 
A large number of the differentially expressed genes in SA were identified as ncRNA. 
ncRNA has a important role in transcriptional and post-transcriptional regulation.25 We 
also identified 12 genes out of a list of 97 well-replicated asthma susceptibility genes in 
our list of 1378 DE genes, of which four were identified from GWA studies in asthma 
(RORA, PDE4D, IL2RB and ORMDL3). The majority were upregulated in CA, which 
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might be a consequence of that most association studies/GWAs are performed on a 
more controlled asthma phenotype. 
 
Taken together, the data indicate a separation in gene expression patterns between 
children with severe, therapy resistant asthma and controlled asthma. It also reveals 
novel pathways characterizing the severe thearapy-resistent asthma phenotype. 
 
In study IV, whole white blood cells were used for investigation of gene expression. As 
discussed above, the problem of knowing which cell type to use for investigation is 
applies here as well. Using whole white blood cells for our study was first of all 
motivated by the fact that the immune system is a large component in the etiology of 
asthma, secondly by the fact that withdrawal of blood is a less invasive procedure for 
the children compared to e.g. an airway biopsy. An obvious disadvantage is that we do 
not know which of the cell/cells in WBC that contributes to the effect seen. The 
observed effect might also be diluted by the fact that cell types showing differential 
expression for a certain gene are mixed with cell types not showing any differential 
expression. To obtain freshly separated cell populations for such a large number of 
study subjects (n=60) collected all over the country was however not feasible since 
RNA is a very instable molecule and will rapidly degrade if not immediately taken care 
of in a proper way. 
 
When assessing direct changes in the DNA (as discussed in 2.3.2.1), cell type and 
timing is less important. When investigating indirect changes e.g. methylation studies 
and RNA expression, both the cell type and the timing matters. Following stimulation 
of cells with an agent (e.g. NPS or LPS), the gene expression appears different if you 
wait 2, 6 or 24 h after stimulation. In the same manner, a blood sample retrieved from a 
patient one day might have a totally different expression profile the next day. Taking 
this in to account, the chance of identifying differentially expressed genes acting in a 
common network, and expressed at the same time and in the same manner within a 
group of patients might be slim. When such genes nonetheless are identified, it is 
strongly indicative of them being important players.  
 
The array technology, followed by next generation sequencing creates, enormous 
amounts of data. We need to learn how to sieve through the data flow in order to extract 
the maximal amount of information. Even when data from a relatively small study, as 
in study IV, are explored, there might be more information than we can process. As an 
example, the gene ontology or enrichment analysis commonly investigated in these 
types of studies can only identify already pre-defined pathways and categories. Even 
though identification of such pathways, as the upregulation of bitter taste receptors in 
severe asthmatics, might lead to novel and significant information, there might still be 
important data that we miss, due to the fact that we do not know what to search for. 
 
 
5.4 BIOLOGICAL EFFECTS (I, II, III) 
In the insatiable search for new disease candidate genes, supported by the technology 
explosion in genomics, it should be acknowledged that it is seldom the finding of the 
gene that cures the disease, but unraveling the function of it might do so. In this thesis 
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we have mainly performed functional studies on one of the asthma susceptibility genes, 
NPSR1. 
 
The downstream signaling properties of the NPSR1 variant A stimulated with its ligand 
NPS have been previously investigated by our group 99, which led us in study III  to 
investigate the signaling properties downstream  NPSR1 variant B, and compare that to 
variant A. In contrast to our previous investigation of NPSR1-A signaling (utilizing a 
stable overexpressing HEK293 cell line) 99, we used transiently NPSR1-A and -B 
overexpressing HEK293 cells this time. The protein expression of both receptor 
variants on the plasma-membrane was determined by flow cytometry, using antibodies 
targeting the common N-terminal. The flow cytometry analysis revealed that the 
intensity of antibody-bound receptor on each cell was similar, both before and after 
NPS stimulation with equal number of positive cell counts, showing that the 
transfection efficiency between the two isoforms was similar, as well as the number of 
membrane bound receptors. When the downstream second messenger response of 
cAMP and Ca2+ was assayed, a similar pattern as for the expression analysis was seen. 
Taken together, NPSR1 variant A generated a greater response than variant B, which 
was also seen by downstream activation of various transcription factor complexes.  
 
Previous studies investigating the functional properties of NPSR1 have mainly focused 
on differences in the NPSR1 variant A expressing either the amino acid 107Asn or 107Ile 
in the first extracellular loop of the receptor protein. Receptors carrying the 107Ile 
variant has been proven to be more potent compared to those expressing the 107Asn 
variant.96-98, 158 Some studies have also assessed differences between variant A and B 
(expressing either 107Asn or 107Ile).96-98 The constructs used in our studies both express 
107Ile, which is also the only present variant in rodents. The results from previous 
studies have varied from no differences in second messenger response between A and 
B 96, 97, to reported differences98. There have also been problems with achieving 
NPSR1-A and -B transient transfection systems to work, and in cases where stable 
systems have been compared to transient systems, the result has not been entirely 
similar. Our results (functional assays together with expression data), however, point 
towards differences in downstream effect between the two receptor isoforms, with 
NPSR1 variant A being a stronger inducer of downstream signaling than B. 
 
A functioning phosphorylation of GPCRs is important for desensitization and rapid 
turnover, altering these sites has been demonstrated to affect the internal signaling 
properties of GPCRs.125-128 Phosphorylation sites are situated in the third intracellular 
loop and in the C-terminus of GPCRs (see Fig. 4). Since the NPSR1 variants display 
distinct C-terminus, the number of phosphosrylation sites differ between the receptors, 
the A variant contains five whereas variant B only harbors two. In an attempt to 
understand what causes the different signaling properties between the receptor variants, 
we examined phosphorylation sites in the C-terminus. Residues in the C-terminal 
targeted for phosphorylation were exchanged to a neutral alanine, which diminished the 
phosphorylation sites. Expression of downstream target genes was investigated in NPS 
stimulated HEK293 cells overexpressing the altered NPSR1 constructs. However, 
alterations of phosphorylation sites could not explain the differences in signaling 
properties between the two receptor variants. 
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In study II, we investigated NPSR1-A and -B expression on the cell membrane of white 
blood cells with flow cytometry. CD14+ PBMCs from 10 blood donors were 
stimulated with or without LPS and specific antibodies for the two receptor variants 
were used for detection. Both isoforms were detected on the cell membrane in a similar 
intensity, but only the A variant responded to LPS treatment with a significant 
upregulation of the receptor protein on the cell membrane. In study I, we used IHC for 
detection of NPSR1-B and TNC protein in bronchial biopsies obtained from asthmatic 
patients and healthy controls. Both genes exhibited an upregulation in the asthmatic 
patients.  NPSR1-B was expressed in the epithelial cells, whereas TNC was mainly 
observed in the sub-epithelial basement membrane layer. 
 
Taken together, functional studies on candidate genes can help us to understand why a 
gene might be a genetically linked susceptibility gene for disease. As discussed in 
section 5.3, it is important to perform the experiments using different cell types and 
tissues to get a full picture, but all pieces of the puzzle are important.   
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6 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
 
Complex diseases are called “complex” for a reason. Most likely, many small changes 
in the genome, which differ between individuals, and environmental influences may 
give rise to the same phenotypic feature. Large scale a priori studies, such as GWA 
studies and NGS, are crucial to identify where to start looking. However small, more 
targeted studies with clearly defined phenotypes are needed to unravel pathways and 
networks leading to the specific disease state. The genes and changes along these 
pathways might be distinct in different groups of patients, however in the end they will 
make up the same phenotype. Once pathways and networks leading to a certain disease 
are defined, we can pinpoint target genes for therapy. These target genes might not be 
identified through genetic analysis, but the genetic analysis made it possible to identify 
where to look. 
 
The results from one single study (association, interaction, expression or biological) are 
regarded as interesting. However, replication of a finding is what validates the results, 
and all these studies (study I, II, III, IV) would benefit from independent replications. 
 
There is a discrepancy in the expression pattern between the two NPSR1 variants where 
e.g. A protein is uniquely expressed in the enteroendocrine cells in the gut. 91 The A 
variant is also the only variant upregulated in monocytes, both on RNA and protein 
level, by LPS stimulation. LPS also acts as a ligand for Toll-like receptors, which are 
expressed on enteroendocrine cells.159 The B variant, on the other hand, is upregulated 
in asthmatic airways and the only gene that was stronger induced by NPS-NPSR1-B 
signaling was CD69, an early activator of Tregs. By creating a transgenic NPSR1-A or -
B overexpressing mouse one could expand the environmental findings and investigate a 
possible connection between NPSR1 and microbial environment. It would also be 
interesting to assess differences between NPSR1 variant A and B in mouse models of 
asthma.   
 
Our identification of upregulated bitter taste receptor (TAS2R) mRNA expression in 
white blood cells, primarily seen in severe therapy-resistant asthmatic childen, is a 
novel finding. Taken together with recent data which reported that TAS2Rs in the 
airways seems to act through a protective mechanism, where e.g. administration of 
bitter tastants caused relaxation of the airways in a mouse model of allergic 
inflammation, this network of TAS2Rs might provide totally new insight into the 
characteristics of asthma. However, the role of TAS2Rs in immune cells needs to be 
thoroughly investigated. First of all our finding needs to be replicated in an 
independent, however phenotypically closely related, study group. Secondly, by 
separating white blood cells in their subgroups (neutrophils, eosinophils, basophils, 
lymphocytes (B, T etc.) and monocytes), the exact expression pattern of TAS2Rs needs 
to be examined. Thirdly, the role that TAS2Rs play in the immune cells needs to be 
identified. The third point could be addressed in vitro by investigating the effect of 
stimulating cells with agonists for bitter taste receptors, by introducing antagonists or 
selective knock-down of the receptors in functional studies, or by assessing the 
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expression pattern of TAS2Rs after interventions that change the function of 
immunocompetent cells. The cause of severe therapy-resistant asthma is poorly 
understood and novel therapeutic approaches are required for this group of patients. 
The findings of the significantly upregulation of the TAS2R pathway in this specific 
group of patients is a new discovery that should be further exploited. It introduces the 
potential of an important endogenous protective system that may be a new therapeutic 
target in asthma. 
 
Epigenetic studies are not within the scope of this thesis. It would, however, be 
interesting to investigate if the protective effect of prenatal and early-life farm exposure 
partially are due to epigenetic changes, and if these changes can be passed on to the 
next generation. The vision is that I may pass on to my children the protective effects 
that my mother introduced to me by living and working on a farm even though I am not 
currently exposed to farm life. 
 
Clearly, more work is needed to fully understand the complex disease of asthma, but 
genetic studies hold the promise of providing the basis for discoveries aimed at treating 
asthmatic patients. 
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Sven-Erik’s grupp. Speciellt tack till Anna, Mikael och Ingrid som hjälpt till med 
artikel II och III. 
 
PARSIFAL-G gruppen. Göran, Annika, Anna, Marianne, Magnus, Fredrik och Erik. 
Jag lärde mig otroligt mycket under stötandet och blötandet av de två interaktions 
artiklarna. Er expertis är inspirerande. 
 
Gruppen på Astrid Lindgrens barnsjukhus. Gunilla, Christophe, Jon, Björn, Erik, Ann, 
Catharina. Vilket otroligt roligt och intressant samarbete vi har initierat. Det känns 
alltid så mycket mer motiverande att bedriva forskning när det faktiskt handlar om 
riktiga patienter.  
 
Mina vänner, insamlade från gymnasietiden i Norrköping, universitets-studier i 
Uppsala och tillskansade via Kristians tid i Uppsala.  Kommer ni ihåg att jag finns trots 
att jag aldrig hör av mig? Jag tror att vi alla är i en fas i livet där vi önskar att vi kunde 
träffas mycket mer än vad vi gör. Men ni ska veta att jag tycker så mycket om er och 
det är så kul när vi väl träffas! 
 
Mina kära, kära systrar. Anna, Eva och Gunilla. Om det är någon jag skulle ringa mitt i 
natten (och jag inte vill väcka Kristian) så är det ni. Ni betyder oerhört mycket för mig 
och att veta att ni alltid finns där är en otrolig trygghet. Ni och era familjer är allt bra 
härliga!  
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Mina kära, kära föräldrar, Ingela och Sigward. Tack för att jag fick växa upp på en 
bondgård, varken astma eller allergi så långt ögat kan se . Tack för att ni alltid har 
uppmuntrat mig att se världen och studera. Ni är alltid positiva och finns där när jag 
behöver stöd och råd, i smått som i stort. Tack också för att ni ställt upp och tagit hand 
om Thea när pusslet inte alltid gått att lösa. 
 
Thea, och du där inne som ligger och sparkar i magen, mina älskade älskade barn. Det 
är ni som är livet… 
 
Kristian, min älskade älskade man, det är du som håller mig under armarna och gör att 
jag kan leva livet… 
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